News

Categories

September 16, 2024

Zymeworks Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024

September 9, 2024

Zymeworks Showcases New and Updated Clinical Data for Zanidatamab at ESMO 2024

August 22, 2024

Zymeworks Announces Participation in Upcoming Investor Conferences

August 1, 2024

Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock

August 1, 2024

Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results

July 30, 2024

Zymeworks Announces Participation in Upcoming Investor Conferences

July 25, 2024

Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

July 22, 2024

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate

July 11, 2024

Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

June 17, 2024

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

June 10, 2024

Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer

May 29, 2024

Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer